ivolumab dose optimization during nivolumab therapy in melanoma patients after achieving a complete, partial or stable response (NIVOPTIMIZE-trial)
Recruiting
- Conditions
- melanomaskin cancer10040900
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 34
Inclusion Criteria
1. Age >= 18 years
2. Advanced or metastatic melanoma or renal cell carcinoma
3. Current treatment with nivolumab in a 480 mg or 6mg/kg, 4 weekly scheme
4. Documented confirmed and ongoing CR, PR or SD according to RECIST v1.1
5. On treatment for at least 6 months
Exclusion Criteria
- Unable to draw blood for study purposes
- Patients willing to participate or already included in the SAFE-STOP trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method